Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of Afimkibart (PF-06480605) in Healthy Chinese Participants
NCT05107492Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2021
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of afimkibart in inflammatory bowel disease (IBD) (2 cohorts), sponsored by Pfizer. Primary endpoints: Maximum Observed Concentration, Time for Cmax and 3 more. Started Nov 2021; status: completed.
02
Drugs
afimkibart
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05107492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107492.